丙型肝炎病毒的血清抗体检测及基因组cDNA扩增

Detection of Serum Antibody to Hqpatitis C Virus and Amplification of Its Genomic cDNA

采用抗HCV-N14和抗HCV-C100-3抗体试剂盒检测丙型肝炎(丙肝)高危人群血液标杯1544人份。丙肝抗体阳性率为:输血后肝炎64.5％、血液透析病人28.6％、肝硬变19.1％、肝细胞癌10.5％、临床非甲非乙型肝炎7.3％、献血员4.1％和医院工作人员2.6％,表明丙型肝炎病毒(HCV)感染在我国相当严重。抗HCV-N4抗体出现较早,且与多聚酶链反应PCR的基因诊断有较好的相关性,是判定HCV感染及其传染性的重要指标。

By using N14 and C100-3, EIA test kits, 1554 blood samples collected from high risk groups of hepatitis C virus (HCV) infection were tested for the presence of anti-HCV. The anti-HCV prevalence was found to be 64.5% in post-transfusion associated hepatitis, 28.6% in hemodialysis patients, 19.1% in liver cirrhosis, 10.5% in hepatocellular carcinoma, 7.3% in clinically diagnosed non A non B hepatitis, 4.1% in paid blood donors and 2.6% in medical staff members, which indicates that HCV infection is very serious in this country. Anti-HCV-N14 seemed to appear in blood earlier than anti-HCV-C100-3, and to have a fair correlation to genomic detection by polymerase chain reaction (PCR). Seroconversion of anti-HCV-N14 can be considered as an important indicator for the judgement on HCV infection and infectivity.